A
Amy P. Abernethy
Researcher at Duke University
Publications - 586
Citations - 29463
Amy P. Abernethy is an academic researcher from Duke University. The author has contributed to research in topics: Palliative care & Population. The author has an hindex of 76, co-authored 586 publications receiving 25420 citations. Previous affiliations of Amy P. Abernethy include University of Technology, Sydney & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Quality of published studies supporting off-label and accelerated approval oncology indications.
Kenneth R. Carson,Y. Chia,J. Sekhar,Remy R Coeytaux,Jane L. Wheeler,C. L. Bennett,Amy P. Abernethy +6 more
TL;DR: The quality of published studies supporting a sample of accelerated approval (AA) and off-label (OL) oncology drug indications was evaluated, since AA/OL indications represent a sub...
Journal ArticleDOI
Beyond metastatic renal cell carcinoma (mRCC) clinical trials: Targeted therapy use and overall survival in community oncology clinics.
Michael R. Harrison,Daniel J. George,Mark S. Walker,Lori L. Hudson,Connie Chen,Beata Korytowsky,Edward J. Stepanski,Amy P. Abernethy +7 more
TL;DR: A retrospective registry of adult mRCC pts from 11 COMM oncology practices, diagnosed since 1/2007 and not enrolled in a trial is reviewed, finding "real world" patterns of use and survival outcomes in mR CC patients treated in community oncologists' settings are unclear.
Journal ArticleDOI
Feasibility Study of a Dose Dense Induction Regimen of High Dose Cytarabine (HiDAC) and Gemtuzumab Ozogamicin (Mylotarg™) for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia.
Arati V. Rao,David A. Rizzieri,Joseph O. Moore,Carlos M. DeCastro,Louis F. Diehl,Amy P. Abernethy,McLean Jordan,Patty Davis,Emily Edmonds,Jon P. Gockerman +9 more
TL;DR: Using primary leukemic cells obtained from these patients, real-time quantitative polymerase chain reaction is being utilised to measure mRNA levels of enzymes involved in the metabolism of cytarabine namely, deoxycytidine kinase, cytidine deaminase, 5′nucleotidase, ribonucleotide reductase, DNA polymerases alpha and beta, and also for levels of hENT1 transporter protein which is responsible for the intracellular transport of cy tar
Journal ArticleDOI
Defining quality, disseminating evidence, and enforcing guidelines for cancer treatment.
TL;DR: The three principal challenges to consistent, high-quality cancer care are defining quality care, disseminating information about those definitions, and enforcing the guidelines that promote them.